Septerna, Inc. Common Stock (SEPN) News
Latest headlines that mention SEPN, newest first · each headline opens the original publisher
- Last price
- $49.49
- Day change
- +1.32%
- Next earnings
- 2026-11-09
SEPN headlines
latest coverageSepterna, a clinical-stage biotech focused on GPCR-targeted therapies, reported significant insider selling in its latest SEC filing.
This clinical-stage biotech focused on GPCR-targeted therapies reported a notable insider sale amid rapid share price appreciation.
SEPN news alerts
Get an alert by email or push when a new headline mentions SEPN.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.